Lynch syndrome cancer vaccines: A roadmap for the development of precision immunoprevention strategies
- PMID: 37035178
- PMCID: PMC10073468
- DOI: 10.3389/fonc.2023.1147590
Lynch syndrome cancer vaccines: A roadmap for the development of precision immunoprevention strategies
Abstract
Hereditary cancer syndromes (HCS) account for 5~10% of all cancer diagnosis. Lynch syndrome (LS) is one of the most common HCS, caused by germline mutations in the DNA mismatch repair (MMR) genes. Even with prospective cancer surveillance, LS is associated with up to 50% lifetime risk of colorectal, endometrial, and other cancers. While significant progress has been made in the timely identification of germline pathogenic variant carriers and monitoring and early detection of precancerous lesions, cancer-risk reduction strategies are still centered around endoscopic or surgical removal of neoplastic lesions and susceptible organs. Safe and effective cancer prevention strategies are critically needed to improve the life quality and longevity of LS and other HCS carriers. The era of precision oncology driven by recent technological advances in tumor molecular profiling and a better understanding of genetic risk factors has transformed cancer prevention approaches for at-risk individuals, including LS carriers. MMR deficiency leads to the accumulation of insertion and deletion mutations in microsatellites (MS), which are particularly prone to DNA polymerase slippage during DNA replication. Mutations in coding MS give rise to frameshift peptides (FSP) that are recognized by the immune system as neoantigens. Due to clonal evolution, LS tumors share a set of recurrent and predictable FSP neoantigens in the same and in different LS patients. Cancer vaccines composed of commonly recurring FSP neoantigens selected through prediction algorithms have been clinically evaluated in LS carriers and proven safe and immunogenic. Preclinically analogous FSP vaccines have been shown to elicit FSP-directed immune responses and exert tumor-preventive efficacy in murine models of LS. While the immunopreventive efficacy of "off-the-shelf" vaccines consisting of commonly recurring FSP antigens is currently investigated in LS clinical trials, the feasibility and utility of personalized FSP vaccines with individual HLA-restricted epitopes are being explored for more precise targeting. Here, we discuss recent advances in precision cancer immunoprevention approaches, emerging enabling technologies, research gaps, and implementation barriers toward clinical translation of risk-tailored prevention strategies for LS carriers. We will also discuss the feasibility and practicality of next-generation cancer vaccines that are based on personalized immunogenic epitopes for precision cancer immunoprevention.
Keywords: DNA mismatch repair deficiency; cancer vaccines; frameshift mutations; immunoprevention; lynch syndrome; microsatellite instability; precision cancer prevention; tumor neoantigens.
Copyright © 2023 Sei, Ahadova, Keskin, Bohaumilitzky, Gebert, von Knebel Doeberitz, Lipkin and Kloor.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures
Similar articles
-
Lynch Syndrome: From Multidisciplinary Management to Precision Prevention.Cancers (Basel). 2024 Feb 20;16(5):849. doi: 10.3390/cancers16050849. Cancers (Basel). 2024. PMID: 38473212 Free PMC article. Review.
-
Recurrent Frameshift Neoantigen Vaccine Elicits Protective Immunity With Reduced Tumor Burden and Improved Overall Survival in a Lynch Syndrome Mouse Model.Gastroenterology. 2021 Oct;161(4):1288-1302.e13. doi: 10.1053/j.gastro.2021.06.073. Epub 2021 Jul 2. Gastroenterology. 2021. PMID: 34224739 Free PMC article.
-
Vaccines for immunoprevention of DNA mismatch repair deficient cancers.J Immunother Cancer. 2022 Jun;10(6):e004416. doi: 10.1136/jitc-2021-004416. J Immunother Cancer. 2022. PMID: 35732349 Free PMC article. Review.
-
Is HLA type a possible cancer risk modifier in Lynch syndrome?Int J Cancer. 2023 May 15;152(10):2024-2031. doi: 10.1002/ijc.34312. Epub 2022 Oct 14. Int J Cancer. 2023. PMID: 36214792 Review.
-
A Frameshift Peptide Neoantigen-Based Vaccine for Mismatch Repair-Deficient Cancers: A Phase I/IIa Clinical Trial.Clin Cancer Res. 2020 Sep 1;26(17):4503-4510. doi: 10.1158/1078-0432.CCR-19-3517. Epub 2020 Jun 15. Clin Cancer Res. 2020. PMID: 32540851 Clinical Trial.
Cited by
-
Precision immuno-oncology approach for four malignant tumors in siblings with constitutional mismatch repair deficiency syndrome.NPJ Precis Oncol. 2024 May 21;8(1):110. doi: 10.1038/s41698-024-00597-8. NPJ Precis Oncol. 2024. PMID: 38773265 Free PMC article.
-
Advances and challenges in cancer immunoprevention and immune interception.J Immunother Cancer. 2024 Mar 21;12(3):e007815. doi: 10.1136/jitc-2023-007815. J Immunother Cancer. 2024. PMID: 38519057 Free PMC article. Review.
-
Lynch Syndrome: From Multidisciplinary Management to Precision Prevention.Cancers (Basel). 2024 Feb 20;16(5):849. doi: 10.3390/cancers16050849. Cancers (Basel). 2024. PMID: 38473212 Free PMC article. Review.
-
Frameshift mutations in peripheral blood as a biomarker for surveillance of Lynch syndrome.J Natl Cancer Inst. 2024 Jun 7;116(6):957-965. doi: 10.1093/jnci/djae060. J Natl Cancer Inst. 2024. PMID: 38466935 Free PMC article.
-
The Past and Future of Inflammation as a Target to Cancer Prevention.Cancer Prev Res (Phila). 2024 Apr 2;17(4):141-155. doi: 10.1158/1940-6207.CAPR-23-0423. Cancer Prev Res (Phila). 2024. PMID: 38271694
References
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials